© 2020 MJH Life Sciences and Targeted Oncology. All rights reserved.
© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
May 25, 2020
"Our efforts in the cancer clinic have been driven by patient safety and also maintaining patient access to care. In the age of COVID-19, those 2 things are sometimes at odds with each other."
May 20, 2020
"Liquid biopsy is useful at any time when a physician needs genomic information about their patient’s cancer in order to make a treatment decision."
May 15, 2020
"Intravesical nadofaragene firadenovec [recombinant adenovirus interferon alpha achieved a 53.4% CR rate in patients with BCG-unresponsive carcinoma in situ of the bladder."
April 28, 2020
Interim findings of the ongoing phase II ZENITH20 trial demonstrated that poziotinib induced a 68.7% disease control rate when used as treatment of patients with pretreated non–small cell lung cancer harboring an EGFR exon 20 insertion.